• Home
  1. Home
  2. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
Scientific article
English

New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance

Contributors

Rodriguez Aller, Marta Ruth; Guinchard, Sylvie; Guillarme, Davy; Pupier, Marion; Jeannerat, Damien; Rivara-Minten, Elisabeth; Veuthey, Jean-Luc; Gurny, Robert

Published in

European journal of pharmaceutics and biopharmaceutics, vol. 95, no. Part B, p. 203-214

Publication date

2015

Abstract

Latanoprost is a practically insoluble prostaglandin F2α analog considered a first-line agent for glaucoma treatment. From a pharmaceutical point of view, latanoprost is challenging to be formulated as an eye drop due to its poor water solubility and the presence of an ester bond that needs to be cleaved in vivo but maintained unchanged during storage. Cyclodextrins (CDs) are known to form complexes with hydrophobic drugs, influencing their stability, availability, solubility, and tolerance in a non-predictable manner. A variety of CDs including native α, β, and γCDs as well as substituted hydroxypropylβCD, hydroxypropylγCD, dimethylβCD, sulphatedβCD, and propylaminoβCD were screened and the most appropriate CD for the formulation of latanoprost for an ocular topical application was selected. Among the tested CDs, propylaminoβCD had the best trade-off between latanoprost stability and availability, which was confirmed by its complex constant value of 3129 M−1. Phase-solubility and NMR investigations demonstrated that the propylaminoβCD effectively formed a complex involving the ester group of latanoprost providing protection to its ester bond, while ensuring proper latanoprost solubilization. Furthermore, in vivo experiments demonstrated that the latanoprost-propylaminoβCD formulation led to lower ocular irritation than the commercial latanoprost formulation used as a reference. The latanoprost-propylaminoβCD formulation was demonstrated to successfully address the main stability, solubility, and tolerance limitations of topical ocular latanoprost therapy for glaucoma.

Keywords

  • Latanoprost
  • Cyclodextrins
  • Propylaminoβcyclodextrin
  • Stability
  • Ex vivo availability
  • Complex structure
  • Complexation
  • Ocular irritation

UNIGE affiliation entities

Citation (ISO format)

RODRIGUEZ ALLER, Marta Ruth et al. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance. In: European journal of pharmaceutics and biopharmaceutics, 2015, vol. 95, n° Part B, p. 203–214. doi: 10.1016/j.ejpb.2015.04.032

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

http://linkinghub.elsevier.com/retrieve/pii/S093964111500212X

Journal ISSN

0939-6411
702views
1downloads

Technical informations

Creation

11/10/2015 15:22:00

First validation

11/10/2015 15:22:00

Update

14/03/2023 23:42:39

Status update

14/03/2023 23:42:39

Last indexation

31/10/2024 01:33:52
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated